期刊文献+

六君子汤加减方治疗脾气虚弱型晚期胃癌的临床疗效 被引量:8

Clinical efficacy of modified Liujunzi Decoction in treatment of patients with advanced gastric cancer differentiated as type of deficiency of spleen qi
下载PDF
导出
摘要 目的分析六君子汤加减方治疗脾气虚弱型晚期胃癌的临床效果。方法将100例脾气虚弱型晚期胃癌患者按照治疗方式分为对照组与观察组,每组50例。所有患者均给予阿帕替尼片治疗,对照组在此基础上加服甲氧氯普胺片,观察组加服六君子汤加减方,观察2组临床效果。结果观察组总有效率及不良反应发生率显著优于对照组(P<0.05)。结论六君子汤加减方治疗脾气虚弱型晚期胃癌疗效显著,且不良反应发生率较低。 Objective To analyze the clinical effect of Liujunzi Decoction in treatment of patients with advanced gastric cancer differentiated as type of deficiency of spleen qi.Methods A total of 100 patients with advanced gastric cancer differentiated as type of deficiency of spleen qi were divided into control group and observation group,with 50 cases in each group.All the patients were treated with apatinib tablets.On this basis,the control group was treated with metoclopramide tablets,while the observation group was treated with modified Liujunzi Decoction.The clinical effect was compared between the two groups.Results The total effective rate and the incidence rate of adverse reactions in the observation group were significantly better than those in the control group(P<0.05).Conclusion Modified Liujunzi Decoction is effective in the treatment of patients with advanced gastric cancer differentiated as type of deficiency of spleen qi,and has iower incidence rate of adverse reactions.
作者 李东 王皓云 管伟 LI Dong;WANG Haoyun;GUAN Wei(Department of Oncology,The First People′s Hospital of Changzhou,Changzhou,Jiangsu,213003;Department of Traditional Chinese Medicine,Tianning Street Community Hospital of Changzhou,Changzhou,Jiangsu,213003;Department of Oncology,Huaiyin Hospital of Huai′an,Huai′an,Jiangsu,223300)
出处 《实用临床医药杂志》 CAS 2019年第21期41-42,47,共3页 Journal of Clinical Medicine in Practice
关键词 六君子汤 脾气虚弱 晚期胃癌 疗效 不良反应 阿帕替尼 甲氧氯普胺 Liujunzi Decoction deficiency of spleen qi advanced gastric cancer efficacy adverse reactions apatinib metoclopramide
  • 相关文献

参考文献13

二级参考文献70

  • 1Yang L,Li LD,Chen YD.Estimate and prediction of mortality of malignant tumor in China in 2000 and 2005.Chin J Health Statistics (Chin) 2005; 22:218-231:.
  • 2Ajani JA,Fodor MB,Tjulandin SA,Moiseyenko VM,Chao Y,Cabral Filho S,et al.Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric,or gastroesophageal adenocarcinoma.J Clin Oncol 2005; 23:5660-5667.
  • 3Murad AM,Santiago FF,Petroianu A,Rocha PR,Rodrigues MA,Rausch M.Modified therapy with 5-fluorouracil,doxorubicin,and methotrexate in advanced gastric cancer.Cancer 1993; 72:37-41.
  • 4Dank M,Zaluski J,Barone C,Valvere V,Peschel C,Wenczl M,et al.Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in lst-line advanced gastric cancer patients.J Clin Oncol 2005; 23(16 suppl):4003.
  • 5Di Bartolomeo M,Buzzoni R,Mariani L,Ferrario E,Katia D,Gevorgyan A,et al.Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma.A randomized phase Ⅲ trial.Oncology 2006; 7 1:341-346.
  • 6Webb A,Cunningham D,Scarffe JH,Harper P,Norman A,Joffe JK,et al.Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer.J Clin Oncol 1997; 15:261-267.
  • 7Wils JA,Klein HO,Wagener DJ,Bleiberg H,Reis H,Korsten F,et al.Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer:a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.J Clin Oncol 1991;9:827-831.
  • 8Vanhoefer U,Rougier P,Wilke H,Ducreux MP,Lacave AJ,Van Cutsem E,et al.Final results of a randomized phase Ⅲ trial of sequential high-dose methotrexate,fluorouracil,and doxorubicin versus etoposide,leucovrin,and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer:a trial of the European Organization for Research and treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.J Clin Oncol 2000; 18:2648-2657.
  • 9Dank M,Zaluski J,Barone C,Valvere V,Yalcin S,Peschel C,et al.Randomized phase Ⅲ study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.Ann Oncol 2008; 19:1450-1457.
  • 10Cunningham D,Allum WH,Stenning SP,Thompson JN,Van de Velde CJ,Nicolson M,et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med 2006; 355:11-20.

共引文献578

同被引文献94

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部